Acquiring Company
Merck
Acquired Company
Terns Pharmaceuticals
RahwayFoster CityManufacturingBiotechnologyHealthcareHealth CareBiotechnologyHealthcareTherapeuticsPharmaceuticalBiopharmaDescription
Merck has announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, totaling an equity value of approximately $6.7 billion. This acquisition aims to enhance Merck's oncology portfolio, particularly in hematology with TERN-701, a candidate for treating chronic myeloid leukemia. The transaction is approved by both companies' boards and reflects a strategic move to strengthen Merck's presence in cancer therapies.
Quick answer
Merck is acquiring Terns Pharmaceuticals for $6.7 billion, announced March 25, 2026. Merck is based in Rahway, New Jersey, United States.
- How much did Merck pay for Terns Pharmaceuticals?
- The reported deal value is $6.7 billion.
- What does Merck do?
- For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our..
- Where are Merck and Terns Pharmaceuticals based?
- Merck is based in Rahway, New Jersey, United States. Terns Pharmaceuticals is based in Foster City, California, United States.
- Who are the decision-makers at Merck?
- Fundz holds 3 contacts at Merck. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
- Eli Lilly to acquire Centessa Pharmaceuticals (March 31, 2026)
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- GSK to acquire 35Pharma for HS235 development (February 25, 2026)
- Cyclerion to merge with Korsana Biosciences (April 1, 2026)
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Terns Pharmaceuticals?
Terns Pharmaceuticals was acquired by Merck, based in Rahway. The deal was reported on March 25, 2026. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire Terns Pharmaceuticals?
Merck's acquisition of Terns Pharmaceuticals was reported on March 25, 2026. Merck has announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, totaling an equity value of approximately $6.7 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Terns Pharmaceuticals do?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. It is privately held, operating in Biotechnology, and is based in Foster City.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.